TY - JOUR
T1 - Optimal management of metastatic castration-resistant prostate cancer
T2 - Highlights from a European Expert Consensus Panel
AU - Fitzpatrick, John M.
AU - Bellmunt, Joaquim
AU - Fizazi, Karim
AU - Heidenreich, Axel
AU - Sternberg, Cora N.
AU - Tombal, Bertrand
AU - Alcaraz, Antonio
AU - Bahl, Amit
AU - Bracarda, Sergio
AU - Di Lorenzo, Giuseppe
AU - Efstathiou, Eleni
AU - Finn, Stephen P.
AU - Fosså, Sophie
AU - Gillessen, Silke
AU - Kellokumpu-Lehtinen, Pirkko Liisa
AU - Lecouvet, Frédéric E.
AU - Oudard, Stephane
AU - De Reijke, Theo M.
AU - Robson, Craig N.
AU - De Santis, Maria
AU - Seruga, Bostjan
AU - De Wit, Ronald
N1 - Funding Information:
The authors would like to thank Julian Lee Lokey, MD, and Sanneke Koekkoek, BSN, for assistance with data collection; Tristin Abair, PhD, and Julian Lee Lokey, MD, for their assistance in drafting this manuscript; and Trudy Grenon Stoddert, ELS, for editorial assistance and assistance preparing the manuscript for submission. All were compensated by prIME Oncology. Financial support was provided by an educational grant from Sanofi Oncology .
PY - 2014/1/1
Y1 - 2014/1/1
N2 - The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.
AB - The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.
KW - Abiraterone
KW - Cabazitaxel
KW - Circulating tumour cells
KW - Consensus
KW - Denosumab
KW - Docetaxel
KW - Enzalutamide
KW - Metastatic castration-resistant prostate cancer
KW - Radium 223 dichloride
KW - Sipuleucel-T
UR - http://www.scopus.com/inward/record.url?scp=84901231924&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2014.03.010
DO - 10.1016/j.ejca.2014.03.010
M3 - Review article
C2 - 24703899
AN - SCOPUS:84901231924
SN - 0959-8049
VL - 50
SP - 1617
EP - 1627
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 9
ER -